By Justin Petrone

It's a "buyer's market" if you're considering acquisitions, and Affymetrix is open to acquiring new technologies in the near future, company officials said last week.

If the array vendor buys a company or platform, it will most likely be in the biomarker-validation market, where the company sees its future, and definitely not in the next-generation sequencing space.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.